Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

10/02/2026, 12:15 PM • The Motley Fool

Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026

Nasdaq announced that Moderna, Inc. (MRNA) will replace Warner Bros. Discovery, Inc. (WBD) as a component of the Nasdaq-100 Index effective October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion in assets under management globally.

10/01/2026, 8:00 PM • GlobeNewswire

Prediction: Moderna Stock Will Soar 100% by 2030

Moderna has rebounded from pandemic-era lows with a diversified product portfolio including COVID, RSV, and flu vaccines, plus promising oncology pipeline candidates. The analyst predicts 100% stock appreciation by 2030 based on potential revenue growth to ~$3 billion and positive pipeline data, though acknowledges manufacturing challenges for personalized cancer vaccines and current high valuation multiples.

09/30/2026, 2:05 PM • The Motley Fool

Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings

U.S. markets rose midday on September 30, 2026, following softer-than-expected August PCE inflation data (3.4% year-over-year), which reduced expectations for an October rate hike. The Nasdaq Composite led gains at +0.99%, while the S&P 500 and Dow Jones showed more modest gains. However, analysts warn of concentration risk in AI stocks and deteriorating market breadth, with single-stock volatility rising despite major indexes near all-time highs.

09/30/2026, 12:19 PM • The Motley Fool

Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?

Moderna's stock has surged over 550% in 2026 following positive Phase 3 trial results for intismeran, a personalized cancer vaccine developed with Merck for melanoma treatment. Despite the excitement and analyst upgrades, the author argues the stock is overvalued at current levels (~$200), with consensus price targets around $77, and cautions against buying at these valuations.

09/28/2026, 10:28 AM • The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

09/03/2026, 5:30 PM • The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.

09/03/2026, 11:10 AM • The Motley Fool

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

09/02/2026, 3:10 PM • The Motley Fool

Stock Market Today, Sept. 1: Stocks Slide and Oil Surges Amid U.S.-Iran Tension

U.S. stock markets declined on September 1, 2026, as rising crude oil prices and Treasury yields pressured equities following escalating U.S.-Iran tensions. The S&P 500 fell 0.71%, the Dow dropped 0.79%, and the Nasdaq declined 1.03%, with technology stocks leading the selloff. Growth stocks underperformed value stocks, while oil surged 5%.

09/01/2026, 5:02 PM • The Motley Fool

Down More Than 30% From Its Peak, Is Now the Perfect Time to Buy Sandisk Stock?

Sandisk stock has fallen over 30% from its all-time high despite being the S&P 500's best performer this year with ~550% gains. The article argues this is a buying opportunity as supply-demand imbalances in NAND memory chips continue to drive price increases. With Wall Street expecting 142% revenue growth for fiscal 2027 and the stock trading at only 7x forward earnings compared to 30x at year-end, the author suggests the stock could double or quadruple if valuations normalize.

09/01/2026, 4:18 PM • The Motley Fool

VOO vs. RSP: If AI Stocks Get Too Concentrated, Here's Which One I'd Choose

The Vanguard S&P 500 ETF (VOO) has become heavily concentrated in mega-cap tech stocks, with its top 10 holdings accounting for nearly 40% of assets and surpassing dot-com bubble concentration levels. The Invesco S&P 500 Equal Weight ETF (RSP) offers an alternative by weighting all 500 S&P 500 stocks equally, reducing concentration risk. While VOO has delivered strong returns driven by AI enthusiasm, the author suggests switching to RSP if concentration exceeds 50% to protect against potential AI stock corrections.

08/30/2026, 6:24 AM • The Motley Fool

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

08/26/2026, 9:46 AM • GlobeNewswire

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

08/26/2026, 9:44 AM • GlobeNewswire

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

08/23/2026, 7:15 AM • The Motley Fool

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

08/22/2026, 8:19 AM • The Motley Fool